$1.07
+0.01 (+0.94%)
Open$1.05
Previous Close$1.06
Day High$1.08
Day Low$1.00
52W High$5.30
52W Low$1.07
Volume—
Avg Volume80.1K
Market Cap2.79M
P/E Ratio—
EPS$1.07
SectorBiotechnology
Analyst Ratings
Strong Sell
7 analysts
Price Target
+2,575.7% upside
Current
$1.07
$1.07
Target
$28.63
$28.63
$25.08
$28.63 avg
$44.18
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 266.6K | 582.2K | 3.56M |
| Net Income | -4,605,408 | -9,051,904 | 452.9K |
| Profit Margin | -1,727.8% | -1,641.4% | 12.7% |
| EBITDA | -22,860,426 | -47,428,269 | 509.0K |
| Free Cash Flow | — | — | 445.4K |
| Rev Growth | -54.2% | -54.2% | +0.2% |
| Debt/Equity | — | — | 0.51 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.53 | -1.09% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $361.16 | +0.17% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.13 | -0.16% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $494.74 | -0.98% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $628.06 | -0.59% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $297.43 | +1.33% | 69.3 | 39.97B |